Lethargic Depression Study

A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of
flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for
eight weeks for the treatment of adult outpatients with major depressive disorder including
symptoms of decreased energy, pleasure, and interest

Inclusion criteria:

- Primary diagnosis of MDD with current duration lasting 12 weeks but no greater than 2
years.

- Generally in good health.

- Subject must read and write at a level sufficient to provide written informed
consent.

Exclusion criteria:

- Current or past history of seizure disorder.

- Subject has a primary diagnosis or received treatment for panic disorder, obsessive
compulsive disorder (OCD), post traumatic stress disorder (PTSD), acute stress
disorder, Bipolar I or II disorder, schizophrenia, or other psychotic disorder.

- Currently using illicit drugs or other psychotropic drugs.

- Patient poses a current suicidal risk or has attempted suicide in the past 6 months.